Loading...

Recent search criteria

Media
- Media
- Press Releases
- Media Statements
- Media Library
Investors
- Investors
- Investors
- Financial Results
- Announcements
- Financial Calendar
- Investor Events
- Reports and Accounts
Partnering
Careers
- Careers
- Careers
- Working at Ipsen
- Culture

Loading...
English EN Français FR EN
- EnglishEN
- FrançaisFR
Global
< Back
- Global EN FR
- Annual Report EN FR
United States

Brazil

Canada

Australia

China

Singapore

South Korea

Belgium FR

Belgium NL

Ukraine

UK

Germany

France

Nordics

Greece

Italy

Netherlands

Spain

Poland

Russia

Slovakia

Czech Republic

Home
Company
- Company
- Company
- Leadership
- History
- Fondation Ipsen
Science
- Science
- Oncology
- Rare Disease
- Neuroscience
- Products
- R&D
- Pipeline
- Clinical Trials
Responsibility
- Responsibility
- Responsibility
- Environment
- Patients
- People
- Governance
Patients
Stories

Home
Stories
General story

Epizyme welcome to Ipsen

Back

Post navigation

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Epizyme welcome to Ipsen

- 12 August 2022 - 1 mins read

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Post navigation

Share this on social media

IPN price

€110.90

€-0.10 (-0.09%)

Media
Investors
Partnering
Careers

Company
Responsibility
Patients
Stories

Annual Report
Contact us

Terms and Conditions
Cookie Policy
Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2023